Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

463 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study.
Kovari H, Sabin CA, Ledergerber B, Ryom L, Worm SW, Smith C, Phillips A, Reiss P, Fontas E, Petoumenos K, De Wit S, Morlat P, Lundgren JD, Weber R. Kovari H, et al. Among authors: morlat p. Clin Infect Dis. 2013 Mar;56(6):870-9. doi: 10.1093/cid/cis919. Epub 2012 Oct 22. Clin Infect Dis. 2013. PMID: 23090925 Free PMC article.
Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy.
Duval X, Journot V, Leport C, Chêne G, Dupon M, Cuzin L, May T, Morlat P, Waldner A, Salamon R, Raffi F; Antiprotease Cohort (APROCO) Study Group. Duval X, et al. Among authors: morlat p. Clin Infect Dis. 2004 Jul 15;39(2):248-55. doi: 10.1086/422141. Epub 2004 Jul 1. Clin Infect Dis. 2004. PMID: 15307035
Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey.
Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, Rosenthal E, Jougla E, Cacoub P, Salmon D, Chêne G, Morlat P; Agence Nationale de Recherches sur le Sida et les Hépatites Virales EN19 Mortalité Study Group; Mortavic Study Group. Bonnet F, et al. Among authors: morlat p. Clin Infect Dis. 2009 Mar 1;48(5):633-9. doi: 10.1086/596766. Clin Infect Dis. 2009. PMID: 19202627
Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort.
Bruyand M, Thiébaut R, Lawson-Ayayi S, Joly P, Sasco AJ, Mercié P, Pellegrin JL, Neau D, Dabis F, Morlat P, Chêne G, Bonnet F; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Bruyand M, et al. Among authors: morlat p. Clin Infect Dis. 2009 Oct 1;49(7):1109-16. doi: 10.1086/605594. Clin Infect Dis. 2009. PMID: 19705973 Free PMC article.
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE); Mocroft A, Reiss P, Kirk O, Mussini C, Girardi E, Morlat P, Stephan C, De Wit S, Doerholt K, Ghosn J, Bucher HC, Lundgren JD, Chene G, Miro JM, Furrer H. Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), et al. Among authors: morlat p. Clin Infect Dis. 2010 Sep 1;51(5):611-9. doi: 10.1086/655761. Clin Infect Dis. 2010. PMID: 20645862 Free article.
CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.
Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord; Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, Reiss P, Gazzard B, Sharland M, Gutierrez F, Obel N, Kirk O, Miro JM, Furrer H, Castagna A, De Wit S, Muñoz J, Kjaer J, Grarup J, Chêne G, Bucher H. Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord, et al. PLoS Med. 2012;9(3):e1001194. doi: 10.1371/journal.pmed.1001194. Epub 2012 Mar 20. PLoS Med. 2012. PMID: 22448150 Free PMC article.
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.
Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, Poizot-Martin I, Richmond G, Soriano V, Ait-Khaled M, Fujiwara T, Huang J, Min S, Vavro C, Yeo J; VIKING Study Group. Eron JJ, et al. J Infect Dis. 2013 Mar 1;207(5):740-8. doi: 10.1093/infdis/jis750. Epub 2012 Dec 7. J Infect Dis. 2013. PMID: 23225901 Free PMC article. Clinical Trial.
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.
Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group. Ryom L, et al. Among authors: morlat p. J Infect Dis. 2013 May 1;207(9):1359-69. doi: 10.1093/infdis/jit043. Epub 2013 Feb 4. J Infect Dis. 2013. PMID: 23382571 Free PMC article.
463 results